Status:
RECRUITING
Invasive Pneumococcal Disease Study
Lead Sponsor:
Association Clinique Thérapeutique Infantile du val de Marne
Collaborating Sponsors:
Pfizer
Conditions:
Pneumococcal Infections
Pneumococcal Conjugate Vaccine
Eligibility:
All Genders
1-18 years
Brief Summary
After 7 then 13 valent pneumococcal conjugate vaccine implementation in France in children, we will evaluate the impact of this vaccination on invasive pneumococcal disease (IPD). We will describe the...
Eligibility Criteria
Inclusion
- Isolate of Streptococcus pneumoniae from at least one blood culture, or pleural fluid, or joint fluid, or cerebrospinal fluid or other normally sterile body site, or if there is a positive blood PCR.
Exclusion
- Pneumococcal strain not transmetted to National Reference Center for Pneumococci or to Regional Pneumococci Observatory
Key Trial Info
Start Date :
December 13 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2030
Estimated Enrollment :
1369 Patients enrolled
Trial Details
Trial ID
NCT04664556
Start Date
December 13 2010
End Date
January 1 2030
Last Update
October 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ACTIV
Créteil, France, 94000